Literature DB >> 30391362

Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN).

Jorge Ruiz-Medrano1, Javier A Montero2, Ignacio Flores-Moreno3, Luis Arias1, Alfredo García-Layana4, José M Ruiz-Moreno5.   

Abstract

Myopia is a highly frequent ocular disorder worldwide and pathologic myopia is the 4th most common cause of irreversible blindness in developed countries. Pathologic myopia is especially common in East Asian countries. Ocular alterations associated with pathologic myopia, especially those involving the macular area-defined as myopic maculopathy-are the leading causes of vision loss in patients with pathologic myopia. High myopia is defined as the presence of a highly negative refractive error (>-6 to -8 diopters) in the context of eye elongation (26-26.5 mm). Although the terms high myopia and pathologic myopia are often used interchangeably, they do not refer to the same eye disease. The two key factors driving the development of pathologic myopia are: 1) elongation of the axial length and 2) posterior staphyloma. The presence of posterior staphyloma, which is the most common finding in patients with pathologic myopia, is the key differentiating factor between high and pathologic myopia. The occurrence of staphyloma will, in most cases, eventually lead to other conditions such as atrophic, traction, or neovascular maculopathy. Posterior staphyloma is for instance, responsible for the differences between a myopic macular hole (MH)-with and without retinal detachment-and idiopathic MH. Posterior staphyloma typically induces retinal layer splitting, leading to foveoschisis in myopic MH, an important differentiating factor between myopic and emmetropic MH. Myopic maculopathy is a highly complex disease and current classification systems do not fully account for the numerous changes that occur in the macula of these patients. Therefore, a more comprehensive classification system is needed, for several important reasons. First, to more precisely define the disease stage to improve follow-up by enabling clinicians to more accurately monitor changes over time, which is essential given the progressive nature of this condition. Second, unification of the currently-available classification systems would establish standardized classification criteria that could be used to compare the findings from international multicentric studies. Finally, a more comprehensive classification system could help to improve our understanding of the genetic origins of this disease, which is clearly relevant given the interchangeable-but erroneous-use of the terms high and pathologic myopia in genetic research.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  ATN classification system; High myopia; Myopic choroidal neovascularization; Myopic maculopathy; Myopic maculopathy classification; Myopic traction maculopathy; Pathologic myopia; Staphyloma

Mesh:

Year:  2018        PMID: 30391362     DOI: 10.1016/j.preteyeres.2018.10.005

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  61 in total

1.  Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis.

Authors:  Rosa M Coco-Martin; Minal Belani-Raju; Daniel de la Fuente-Gomez; María R Sanabria; Itziar Fernández
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-06-20       Impact factor: 3.117

2.  Observation of macular hole associated with retinoschisis in patients with high myopia.

Authors:  Ke Zhang; Xiaohan Yang; Zengyi Wang; Yanping Yu; Yajie Yu; Lingzi Liu; Biying Qi; Xijin Wu; Wu Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-22       Impact factor: 3.535

3.  Long-term outcome of pathologic myopic foveoschisis treated with posterior scleral reinforcement followed by vitrectomy.

Authors:  Yao Huang; Yue Qi; Wen-Bin Wei; An-Li Duan
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

4.  Choroid automatic segmentation and thickness quantification on swept-source optical coherence tomography images of highly myopic patients.

Authors:  Menghan Li; Jian Zhou; Qiuying Chen; Haidong Zou; Jiangnan He; Jianfeng Zhu; Xinjian Chen; Fei Shi; Ying Fan; Xun Xu
Journal:  Ann Transl Med       Date:  2022-06

Review 5.  Myopic Traction Maculopathy: Diagnostic and Management Strategies.

Authors:  Rino Frisina; Irene Gius; Michele Palmieri; Alessandro Finzi; Luigi Tozzi; Barbara Parolini
Journal:  Clin Ophthalmol       Date:  2020-11-02

6.  Morphological differences between two types of Bruch's membrane defects in pathologic myopia.

Authors:  Jiamin Xie; Qiuying Chen; Guangyi Hu; Yao Yin; Haidong Zou; Jiangnan He; Jianfeng Zhu; Ying Fan; Xun Xu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-10-26       Impact factor: 3.117

7.  Protective effects of riboflavin-UVA-mediated posterior sclera collagen cross-linking in a guinea pig model of form-deprived myopia.

Authors:  Ding Han; Mei-Nan He; Ying Zhu; Yan Zhang; Rui-Hua Wei
Journal:  Int J Ophthalmol       Date:  2021-03-18       Impact factor: 1.779

8.  Time trend of axial length and associated factors in 4- and 5-year-old children in Shanghai from 2013 to 2019.

Authors:  Tao Li; Ting Wan; Xiaoqian Yao; Huihong Qi; Xuefeng Chen; Man She; Qianqian Hu; Xiaodong Zhou
Journal:  Int Ophthalmol       Date:  2020-11-12       Impact factor: 2.031

9.  Efficiency comparison with fovea-sparing internal limiting membrane peeling and complete internal limiting membrane peeling for treating myopic traction maculopathy.

Authors:  Wen-Jian Xin; Ji-Ze Jiang; Lei-Bing Ji; Wen-Juan Lv; Yong-Xin Gu; Yun Xiao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-26       Impact factor: 3.117

10.  Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs.

Authors:  Yifang Yang; Junshu Wu; Defu Wu; Qi Wei; Tan Zhong; Jun Yang; Xiaowei Yang; Meizhen Zeng; Xingwu Zhong
Journal:  Eye Vis (Lond)       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.